November 25, 2025

Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer

Results from a large, prospective study show that eating a less inflammatory diet may reduce the risk of death for patients with stage III colon cancer.

The ASCO Post

November 25, 2025

Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer

For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly impr...

The ASCO Post

November 25, 2025

Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation

Circulating tumor DNA (ctDNA) was found to be a strong prognostic classifier for patients with stage III colon cancer following surgery, according to findings from the phase II/III DYNAMIC-III trial. ...

The ASCO Post

November 25, 2025

Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer

“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born ...

The ASCO Post

November 25, 2025

Preneoplastic and Neoplastic Small Lymphocytic Proliferations

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, ...

The ASCO Post

November 25, 2025

How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research

There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richa...

The ASCO Post

November 25, 2025

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma.

The ASCO Post

November 25, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

November 25, 2025

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’...

The ASCO Post